ABBOTT-CITALOPRAM TABLET

Country: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

CITALOPRAM (CITALOPRAM HYDROBROMIDE)

থেকে পাওয়া:

ABBOTT LABORATORIES, LIMITED

এটিসি কোড:

N06AB04

INN (International Name):

CITALOPRAM

ডোজ:

40MG

ফার্মাসিউটিকাল ফর্ম:

TABLET

রচনা:

CITALOPRAM (CITALOPRAM HYDROBROMIDE) 40MG

প্রশাসন রুট:

ORAL

প্যাকেজ ইউনিট:

100

প্রেসক্রিপশন টাইপ:

Prescription

Therapeutic area:

SELECTIVE-SEROTONIN REUPTAKE INHIBITORS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0136243002; AHFS:

অনুমোদন অবস্থা:

CANCELLED POST MARKET

অনুমোদন তারিখ:

2015-12-31

পণ্য বৈশিষ্ট্য

_ _
_Abbott-Citalopram Product Monograph _
_Page 1 of 48_
PRODUCT MONOGRAPH
PR
ABBOTT-CITALOPRAM _ _
Citalopram Tablets USP
10 mg, 20 mg and 40 mg citalopram (as citalopram hydrobromide)
Antidepressant
BGP Pharma Inc.
8401 Trans-Canada Highway
Saint-Laurent, Quebec
H4S 1Z1
Date of Preparation:
January 7, 2015
Submission Control No.: 180716
_ _
_Abbott-Citalopram Product Monograph _
_Page 2 of 48 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................12
DRUG INTERACTIONS
..................................................................................................19
DOSAGE AND ADMINISTRATION
..............................................................................25
OVERDOSAGE
................................................................................................................27
ACTION AND CLINICAL PHARMACOLOGY
............................................................28
STORAGE AND STABILITY
..........................................................................................29
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................30
PART II: SCIENTIFIC INFORMATION
...............................................................................31
PHARMACEUTICAL INFORMATION
..........................................................................31
CLINICAL TRIALS
.......................................................................................